Optimizing Referral Pathways for Patients With Hematuria and Moderate-Severe Proteinuria
Part of paid clinical trials in Danville, Pennsylvania.
- Sponsor
- Geisinger Clinic
- Study ID
- NCT07431931
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Glomerulonephritis
- Hematuria
- Kidney Disease
- Proteinuria
- Referral and Consultation
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Electronic Health Record alert — OTHERThe EHR alert will open upon logging into patient's chart. It will display relevant information about hematuria (dipstick blood), urine microscopy (if available), proteinuria (ACR, PCR, dipstick protein), most recent (if ever) nephrology visit, and most recent (if ever) urology visit. The EHR alert will provide a preselected order button for a nephrology referral with the indication pre-filled out. It will also provide options to order confirmatory urinalysis with microscopy testing and an option to refer to urology. The provider will have an option to deselect the nephrology referral, which will prompt reasons for not ordering the referral: "Not appropriate"; "already seeing a nephrologist"; "palliative care"; "patient refuses"; "Other (document)". The alert will not be a hard-stop in the chart.
Study Details
The purpose of the study is to evaluate prospectively the impact of an electronic health record (EHR) alert on primary care providers' (PCP) referral to Nephrology of Geisinger patients with high risk signs (blood and protein in the urine) of glomerulonephritis. This will help quantify the relative effectiveness of EHR alerts on PCPs' referral patterns.
Key Dates
- Start date
- Nov 30, 2026
- Status verified
- May 2026
- Primary completion
- Dec 31, 2027
- Completion
- Dec 31, 2027
Study Design
- Enrollment
- 1,200 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- SCREENING
Arms
- Experimental: Patients randomized to have PCP receive EHR Alert
- No Intervention: Patients receiving usual carePatient will receive usual care
Primary Outcome Measure
Referral to Nephrology [ Time Frame: Within One month of index PCP visit ]
Central Contacts
- Alexander Chang, MD570-214-3156
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Geisinger Medical Center | Danville | Pennsylvania | 17822 | - |
Find similar trials in Danville, PA
By research site
Related Studies
- A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and ProteinuriaPHASE3 · Recruiting · Bayer · Phoenix, Arizona
- A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and ProteinuriaPHASE3 · Recruiting · Bayer · Phoenix, Arizona
- A Study of Mezagitamab in Adults With Kidney Condition Called IgA NephropathyPHASE3 · Recruiting · Takeda · Birmingham, Alabama
- Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental GlomerulosclerosisPHASE4 · Recruiting · Travere Therapeutics, Inc. · Birmingham, Alabama